7-Ethyl-[1,2,4]triazolo[4,3-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 7-Ethyl-[1,2,4]triazolo[4,3-a]pyridine
• 英文别名: 7-ethyl-[1,2,4]triazolo[4,3-a]pyridine
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: YGCSXHWVKLTPOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102311A1

  公开（公告）日：2020-04-02

  Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R 2 , R 3 R 4 , R 5 and R 6 are defined herein.

  桥接化合物，其结构式为(I)和(II)，包含它们的药物组合物，制造它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、障碍和状况的方法，如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、难治性抑郁、焦虑性抑郁、双相情感障碍）、癌症和眼科疾病相关的方法。 其中R2、R3、R4、R5和R6的定义如下。
• [EN] ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2<br/>[FR] DÉRIVÉS DE QUINAZOLINE ALCYNE SERVANT D'INHIBITEURS D'ERBB2
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022006386A1

  公开（公告）日：2022-01-06

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  本公开涉及一般用于抑制ErbB2的化合物及其组合物，包括ErbB2的突变形式，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症中的应用，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食道癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结直肠癌、肾癌、膀胱癌或前列腺癌。
• Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon
  申请人：Obshchestvo s ogranichennoy otvetstvennostyou "Fusion Pharma"

  公开号：US20140213592A1

  公开（公告）日：2014-07-31

  The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

  本发明涉及使用新的化学化合物家族辅助治疗肿瘤、慢性炎症和类似疾病，这些化合物家族在抑制Abl激酶及其突变形式以及其他具有治疗意义的激酶方面具有提高的效率。本发明描述了蛋白激酶抑制剂，其形式为通式(I)和通式(II)的化合物，或其互变异构体、单个异构体、异构体混合物、药学上可接受的盐、溶剂或其水合物。
• Modulators of ion channel receptors and uses thereof
  申请人：BIONOMICS LIMITED

  公开号：US11384085B2

  公开（公告）日：2022-07-12

  Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.

  本文公开了有助于调节细胞中离子通道活性的化合物。本公开还涉及这些化合物在治疗疼痛方面的用途，以及含有这些化合物的药物组合物及其制备方法。